MerckInc. (NYSE:MRK) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is
being furnished to this Item 2.02.
Incorporated by reference is a press release issued by the
Registrant on May2, 2017, regarding earnings for the first
quarter of 2017, attached as Exhibit99.1. Also incorporated by
reference is certain supplemental information not included in the
press release, attached as Exhibit99.2.
This information shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
Section, and is not incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits.
|
(d) Exhibits |
|
|
Exhibit99.1 |
Press release issued May2, 2017, regarding earnings for the |
|
Exhibit99.2 |
Certain supplemental information not included in the press |
About Merck & Co., Inc. (NYSE:MRK)
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. Merck & Co., Inc. (NYSE:MRK) Recent Trading Information
Merck & Co., Inc. (NYSE:MRK) closed its last trading session up +0.06 at 62.38 with 10,217,078 shares trading hands.
